Home Health Care Amedisys Inc (NASDAQ:AMED) Analyst Views

Amedisys Inc (NASDAQ:AMED) Analyst Views

1
0
SHARE

Intraday Info: Amedisys Inc (NASDAQ:AMED) locked on 06/02/2017 at $46.19. It has average volume 297.05K whilst it totals volume 142,500. The company has EPS 1.23 and according to analysts next quarter EPS and next year estimate EPS will 0.39 and 1.99 respectively. Profit Margin of AMED 2.90% and it total income 41.30 Million.

Ownership Summary: Amedisys Inc has total institutional ownership 98.07% while its total outstanding shares 34 millions that’s value of holdings $1,532 million.

Active Positions: In the latest year, AMED 71 holders have raised its positions while it contains total 4,515,297 shares. And the strength of reduced positions holders and held positions holders are 82 and 22 respectively.

New and Sold Out Positions: In AMED force of new positions holders 17 and it has total shares 2,229,444. And force of sold out positions holders 21 and it has 506,043 shares.

Comparison with Other Company: The Market Value of AMED is $1M below from Rite Aid Corporation market value which is $5M. Current Last Sale of AMED is $46.19 above from RAD current last sale which is $5.29.

Amedisys announcing promising initial results from a bold new pilot assignment that targets heart failure and plans to roll out the program companywide in February.

In keeping with the CDC, a few 85.6 million people stay with cardiovascular diseases, with an estimated 5.7 million affected by coronary heart failure especially. coronary heart failure is the only main cardiovascular disorder at the rise, and causes more hospitalizations than all sorts of cancer blended.

The Amedisys heart Failure software, a multidisciplinary specialty program in home fitness, currently involves extra than 300 heart failure sufferers at 14 Amedisys care centers at some stage in Alabama. Its precise protocol, drawn from facts amassed through Amedisys and companywide attention groups, is designed expressly to deliver the satisfactory scientific consequences.

The overall “heart Suite” application now underway at Amedisys also encompasses new care protocols for two other diagnoses – Acute Myocardial Infarction (AMI) and Coronary Artery bypass Graft (CABG).